REGENXBIO (NASDAQ:RGNX) Stock Price Down 4.7% - What's Next?

Key Points

• REGENXBIO's stock price decreased by 4.7% to $11.60, with trading volume significantly down by 92% from its average session volume.
• Analyst ratings for REGENXBIO are mixed, with five analysts issuing a Buy rating and a consensus target price of $28.38, while Weiss Ratings maintains a sell rating.
• The company reported a quarterly EPS of ($1.38), missing estimates, with revenue of $21.36 million, compared to a consensus of $40.87 million.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report)'s stock price fell 4.7% on Friday . The stock traded as low as $11.75 and last traded at $11.60. 67,812 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 892,907 shares. The stock had previously closed at $12.17.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of REGENXBIO in a research note on Wednesday. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Monday, September 8th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 target price on shares of REGENXBIO in a research report on Tuesday. Wall Street Zen lowered REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Finally, Barclays decreased their price objective on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating for the company in a report on Friday, August 8th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of "Moderate Buy" and a consensus target price of $28.38.

REGENXBIO Trading Down 7.3%

The business has a fifty day simple moving average of $9.21 and a 200 day simple moving average of $8.65. The stock has a market capitalization of $569.80 million, a P/E ratio of -3.28 and a beta of 1.17.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%.The company had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. As a group, research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Insider Activity

In other news, CEO Curran Simpson sold 7,734 shares of the company's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $10.02, for a total value of $77,494.68. Following the completion of the transaction, the chief executive officer directly owned 244,597 shares of the company's stock, valued at $2,450,861.94. This represents a 3.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 12.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. FNY Investment Advisers LLC bought a new position in REGENXBIO in the 1st quarter valued at $35,000. Brooklyn Investment Group grew its position in REGENXBIO by 163.7% during the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after buying an additional 3,466 shares during the period. Steward Partners Investment Advisory LLC grew its position in shares of REGENXBIO by 754.1% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company's stock valued at $46,000 after acquiring an additional 5,000 shares during the period. Captrust Financial Advisors bought a new position in shares of REGENXBIO during the 2nd quarter valued at approximately $85,000. Finally, Pallas Capital Advisors LLC bought a new position in shares of REGENXBIO during the 1st quarter valued at approximately $74,000. Institutional investors own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.